What is something that is treated as common knowledge or consensus in this community but lacks evidence, is missing nuance, or is simply untrue? Chat 4/25/2026
Common misconceptions about hair loss treatments include the belief that lower doses of finasteride are as effective as higher doses, and that ketoconazole is effective for androgenetic alopecia without scalp issues. Additionally, minoxidil's effects can be seen sooner than commonly thought, and topical dutasteride is effective.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity 31M. Just diagnosed with androgenic alopecia. Fears of min.
A 31-year-old man with androgenic alopecia is considering treatments like finasteride, minoxidil, and ketoconazole shampoo but is worried about finasteride's side effects. Users recommend starting with finasteride or dutasteride for DHT blocking, suggesting topical solutions to reduce side effects.
community 24M seeking help for aggressive androgenetic alopecia - "nuke" stack?
A 24-year-old male with aggressive androgenetic alopecia is using 1mg finasteride daily and considering a treatment stack including 0.5mg dutasteride, 2.5mg oral minoxidil, ketoconazole shampoo, Alpecin caffeine shampoo, and RU58841. He seeks advice on the safety and effectiveness of these treatments and whether any adjustments are needed.
community Does ketokonazole on its own improve androgenetic alopecia?
Ketoconazole can slightly improve hair density and is best used as an adjunct to treatments like finasteride and minoxidil. It helps with scalp health but won't stop androgenetic alopecia on its own.
community Been using Dutasteride, Ru58841, Minoxidil, and Ketaconozole for years. Still can't stop shed, recession or loss of density.
Despite using dutasteride, RU58841, minoxidil, and ketoconazole for years, the user continues to experience severe hair loss and thinning. They seek advice after multiple dermatologists confirmed androgenetic alopecia (AGA) but offered no effective solutions.
community Female 37/F - On Meds, but no progress. Add PRP?
A 37-year-old woman with androgenetic alopecia is using spironolactone, oral and topical minoxidil, and considering PRP therapy due to lack of progress. She is unable to obtain finasteride, dutasteride, or bicalutamide and is exploring other options like Clascoterone and RU58841.
Related Research
6 / 6 resultsresearch Update Treatment of Male Androgenetic Alopecia
This review discusses the treatment options for male androgenetic alopecia, including FDA-approved therapies and new possibilities, but reports no new clinical results.
research Addressing Androgenetic Alopecia-A Complex Disorder-with a Multilateral Treatment Strategy
This review discusses recent advancements in understanding the pathophysiology of androgenetic alopecia and highlights the potential for multilateral topical therapies to improve treatment efficacy with fewer side effects; it reports no new clinical results.
research Treat androgenetic alopecia with antiandrogens, as well as other pharmacological and non-pharmacological interventions
This review discusses current treatment options for androgenetic alopecia, noting that most lack robust evidence for efficacy and safety, highlighting the need for more comprehensive studies.
research Revisión actualizada del tratamiento de la alopecia androgenética femenina
This review of female androgenetic alopecia treatments reports limited therapeutic options due to unclear pathogenesis, with minoxidil as the only FDA-approved treatment and adjuvant therapies under investigation.
research Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA
This pilot study found that a novel regimen including NuH Hair led to significant hair growth in male patients with androgenic alopecia, regardless of atopy status, with quicker results when additional treatment components were used.
research Managing patterned hair loss – a hair raising task!
This review summarizes existing knowledge on diffuse and patterned alopecia, emphasizing recent advancements in treatment beyond FDA-approved options, but it reports no new clinical findings.